Travere Therapeutics Inc [TVTX] stock is trading at $17.40, up 3.20%. An important factor to consider is whether the stock is rising or falling in short-term value. The TVTX shares have lost -2.85% over the last week, with a monthly amount glided 0.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Travere Therapeutics Inc [NASDAQ: TVTX] stock has seen the most recent analyst activity on October 21, 2024, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $27 from $9. On September 09, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $25 on the stock. Guggenheim downgraded its rating to a Neutral. Citigroup upgraded its rating to a Buy and raised its price target to $10 on December 05, 2023. Citigroup started tracking with a Neutral rating for this stock on November 20, 2023, and assigned it a price target of $7. In a note dated September 22, 2023, Wells Fargo downgraded an Equal Weight rating on this stock and revised its target price from $24 to $8.
Travere Therapeutics Inc [TVTX] stock has fluctuated between $5.12 and $20.33 over the past year. Currently, Wall Street analysts expect the stock to reach $21.75 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $17.40 at the most recent close of the market. An investor can expect a potential return of 25.0% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
Travere Therapeutics Inc [NASDAQ:TVTX] reported sales of 203.45M for the trailing twelve months, which represents a growth of 69.56%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -1.69%, Pretax Profit Margin comes in at -1.71%, and Net Profit Margin reading is -1.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -5.42 and Total Capital is -1.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -12.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.87 points at the first support level, and at 16.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.72, and for the 2nd resistance point, it is at 18.05.
Ratios To Look Out For
For context, Travere Therapeutics Inc’s Current Ratio is 1.71. On the other hand, the Quick Ratio is 1.68, and the Cash Ratio is 0.19. Considering the valuation of this stock, the price to sales ratio is 7.44.
Transactions by insiders
Recent insider trading involved Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER, that happened on Nov 25 ’24 when 12090.0 shares were sold. Officer, Calvin Sandra completed a deal on Nov 25 ’24 to buy 12090.0 shares. Meanwhile, Director LYONS GARY A sold 40000.0 shares on Oct 04 ’24.
